Betaferon's Relapsing-Remitting Effect on MS Similar in Different Doses.Summary: TEHRAN (FNA)- A new study for comparing the efficacy of 250 micro/g or 500 micro/g interferon beta-1b with Glatiramer acetate for treating relapsing-remitting multiple sclerosis showed that both doses had similar clinical effects to Glatiramer acetate. The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial, funded by Bayer HealthCare Pharmaceuticals, was to compare the efficacy, safety, and tolerability of 250 micro/g or 500 micro/g interferon beta-1b with Glatiramer acetate for treating relapsing-remitting multiple sclerosis. Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicenter, randomized trial. Patients were randomly assigned 2:2:1 by block randomization randomization (ranˈ·d  ·m with regional stratification to receive one of two
doses of interferon beta-1b (250 micro/g or 500 micro/g) subcutaneously
every other day or 20 mg Glatiramer acetate subcutaneously every day.
The primary outcome was relapse risk, defined as new or recurrent
neurological symptoms separated by at least 30 days from the preceding
event and that lasted at least 24 h. Secondary outcomes were progression
on the expanded disability status scale The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis.[1] The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. (EDSS) and change in
T1-hypointense lesion volume. Clinical outcomes were assessed quarterly
for 2A[cedilla ce·dil·la n. A mark ( ¸ ) placed beneath the letter c, as in the spelling of the French word garçon, to indicate that the letter is to be pronounced (s). ]0-3A[cedilla]5 years; MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. The study found that there are no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalized brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p Patient attrition rates were 17% (153 of 888) on 250 micro/g interferon beta-1b, 26% (227 of 887) on 500 micro/g interferon beta-1b, and 21% (93 of 445) for Glatiramer acetate. According to outcomes, 500 micro/g interferon beta-1b was not more effective than the standard 250 micro/g dose, and both doses had similar clinical effects to glatiramer acetate. Although interferon beta-1b and glatiramer acetate had different adverse event profiles, the overall tolerability to both drugs was similar 2006 Fars News Agency Fars News Agency (FNA) is an Iranian news agency. It was officially launched in Tehran in February 2002 to "promote the principles of the Islamic Revolution and safeguard national interests". . All rights reserved Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion